WuXi Biologics (Cayman) Inc.
WXIBF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $9,953 | $10,101 | $8,574 | $8,542 |
| % Growth | -1.5% | 17.8% | 0.4% | – |
| Cost of Goods Sold | $5,700 | $5,800 | $5,224 | $5,275 |
| Gross Profit | $4,253 | $4,301 | $3,350 | $3,267 |
| % Margin | 42.7% | 42.6% | 39.1% | 38.2% |
| R&D Expenses | $344 | $422 | $344 | $451 |
| G&A Expenses | $781 | $901 | $773 | $816 |
| SG&A Expenses | $1,185 | $1,113 | $1,186 | $1,170 |
| Sales & Mktg Exp. | $270 | $251 | $223 | $189 |
| Other Operating Expenses | $0 | -$388 | $0 | $0 |
| Operating Expenses | $1,529 | $1,147 | $1,530 | $1,621 |
| Operating Income | $2,724 | $3,154 | $1,820 | $1,646 |
| % Margin | 27.4% | 31.2% | 21.2% | 19.3% |
| Other Income/Exp. Net | $604 | -$328 | $189 | -$1 |
| Pre-Tax Income | $3,328 | $2,826 | $2,008 | $1,645 |
| Tax Expense | $571 | $661 | $228 | $412 |
| Net Income | $2,339 | $1,857 | $1,499 | $1,133 |
| % Margin | 23.5% | 18.4% | 17.5% | 13.3% |
| EPS | 0.58 | 0.46 | 0.35 | 0.26 |
| % Growth | 26.1% | 31.4% | 34.6% | – |
| EPS Diluted | 0.55 | 0.43 | 0.35 | 0.26 |
| Weighted Avg Shares Out | 4,240 | 4,082 | 4,304 | 4,485 |
| Weighted Avg Shares Out Dil | 4,186 | 4,227 | 4,256 | 4,348 |
| Supplemental Information | – | – | – | – |
| Interest Income | $121 | $350 | $0 | $65 |
| Interest Expense | $0 | $158 | $0 | $0 |
| Depreciation & Amortization | $725 | $784 | $653 | $498 |
| EBITDA | $3,449 | $3,956 | $2,473 | $2,128 |
| % Margin | 34.7% | 39.2% | 28.8% | 24.9% |